David DiLillo

David DiLillo

Company: Regeneron

Job title: Director, Immuno- Oncology


Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies 12:00 pm

– CD3-engaging bispecific antibodies drive potent anti-tumor activity in pre-clinical models as well as in patients – However, not all patients respond to therapy and many relapse after initially responding – Here, we describe novel therapeutics that engage alternative T cell signaling pathways and demonstrate combinatorial anti-tumor effects in high-bar pre-clinical modelsRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.